RU2011125601A - Фармацевтические композиции токсина клостридий - Google Patents
Фармацевтические композиции токсина клостридий Download PDFInfo
- Publication number
- RU2011125601A RU2011125601A RU2011125601/15A RU2011125601A RU2011125601A RU 2011125601 A RU2011125601 A RU 2011125601A RU 2011125601/15 A RU2011125601/15 A RU 2011125601/15A RU 2011125601 A RU2011125601 A RU 2011125601A RU 2011125601 A RU2011125601 A RU 2011125601A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- excipient
- composition according
- effective amount
- clostridial toxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
1. He содержащая животный белок фармацевтическая композиция клостридиального токсина в твердой форме, содержащая клостридиальный токсин в качестве активного ингредиента, эффективное количество эксципиента сахара и эффективное количество поверхностно-активного эксципиента.2. Композиция по п.1, где эксципиент сахар представляет собой моносахарид, дисахарид или трисахарид.3. Композиция по п.1, где моносахарид представляет собой сахарозу или трегалозу.4. Композиция по п.1, где поверхностно-активный эксципиент представляет собой полоксамер, полисорбат, полиоксиэтиленгликольдодециловый эфир или полиоксиэтиленоктилфениловый эфир.5. Композиция по п.1, где клостридиальный токсин в качестве активного ингредиента стабилен в течение по меньшей мере одного года при хранении при температуре окружающей среды или ниже температуры замерзания.6. Композиция по п.1, где композиция забуферена до рН от приблизительно 5,5 до приблизительно 6,5.7. Композиция по п.6, где композиция забуферена с использованием цитратного буфера, фосфатного буфера, гистидинового буфера или гистидин-фосфатного буфера.8. Композиция по п.1, где композиция дополнительно содержит эффективное количество хлорида натрия.9. Композиция по п.1, где композиция дополнительно содержит эффективное количество небелкового полимерного эксципиента.10. Композиция по п.9, где небелковый полимерный эксципиент представляет собой декстран, полиэтиленгликоль, полиэтиленимин, поливинилпирролидон, поливинилацетат, инулин, крахмал или производное крахмала.
Claims (10)
1. He содержащая животный белок фармацевтическая композиция клостридиального токсина в твердой форме, содержащая клостридиальный токсин в качестве активного ингредиента, эффективное количество эксципиента сахара и эффективное количество поверхностно-активного эксципиента.
2. Композиция по п.1, где эксципиент сахар представляет собой моносахарид, дисахарид или трисахарид.
3. Композиция по п.1, где моносахарид представляет собой сахарозу или трегалозу.
4. Композиция по п.1, где поверхностно-активный эксципиент представляет собой полоксамер, полисорбат, полиоксиэтиленгликольдодециловый эфир или полиоксиэтиленоктилфениловый эфир.
5. Композиция по п.1, где клостридиальный токсин в качестве активного ингредиента стабилен в течение по меньшей мере одного года при хранении при температуре окружающей среды или ниже температуры замерзания.
6. Композиция по п.1, где композиция забуферена до рН от приблизительно 5,5 до приблизительно 6,5.
7. Композиция по п.6, где композиция забуферена с использованием цитратного буфера, фосфатного буфера, гистидинового буфера или гистидин-фосфатного буфера.
8. Композиция по п.1, где композиция дополнительно содержит эффективное количество хлорида натрия.
9. Композиция по п.1, где композиция дополнительно содержит эффективное количество небелкового полимерного эксципиента.
10. Композиция по п.9, где небелковый полимерный эксципиент представляет собой декстран, полиэтиленгликоль, полиэтиленимин, поливинилпирролидон, поливинилацетат, инулин, крахмал или производное крахмала.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12134508P | 2008-12-10 | 2008-12-10 | |
US12/331,816 US8168206B1 (en) | 2005-10-06 | 2008-12-10 | Animal protein-free pharmaceutical compositions |
US12/331,816 | 2008-12-10 | ||
US61/121,345 | 2008-12-10 | ||
PCT/US2009/067538 WO2010090677A1 (en) | 2008-12-10 | 2009-12-10 | Clostridial toxin pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011125601A true RU2011125601A (ru) | 2013-01-20 |
RU2535003C2 RU2535003C2 (ru) | 2014-12-10 |
Family
ID=42154422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011125601/15A RU2535003C2 (ru) | 2008-12-10 | 2009-12-10 | Фармацевтические композиции токсина клостридий |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP2373294B1 (ru) |
JP (5) | JP2012512162A (ru) |
KR (2) | KR20110106346A (ru) |
CN (2) | CN102307571A (ru) |
AU (1) | AU2009339292B2 (ru) |
CA (1) | CA2746425C (ru) |
RU (1) | RU2535003C2 (ru) |
WO (1) | WO2010090677A1 (ru) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
EP2373294B1 (en) * | 2008-12-10 | 2016-04-20 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
SG10201405582YA (en) | 2008-12-31 | 2014-10-30 | Revance Therapeutics Inc | Injectable Botulinum Toxin Formulations |
KR20210141783A (ko) * | 2009-06-25 | 2021-11-23 | 레반스 테라퓨틱스, 아이엔씨. | 알부민불포함 보툴리눔 독소 제제 |
US9173944B2 (en) | 2010-10-12 | 2015-11-03 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
AU2011315962B2 (en) | 2010-10-14 | 2016-06-02 | Allergan, Inc. | Targeted delivery of Targeted Exocytosis Modulators to the sphenopalatine ganglion for treatment of headache disorders |
US20120244188A1 (en) | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20120251573A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Neuroendocrine Disorders |
US20120251575A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Involuntary Movement Disorders |
US20120251574A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
US20120251518A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Sexual Dysfunction Disorders |
WO2012135304A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Vagal nerve-based disorders |
US20120251519A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Smooth Muscle Disorders |
US20120251515A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Cosmesis Disorders |
PT3241547T (pt) * | 2011-03-31 | 2020-08-26 | Medy Tox Inc | Preparação liofilizada de toxina botulínica |
KR101679370B1 (ko) | 2011-06-01 | 2016-11-24 | 바이오메디슨, 인코퍼레이티드 | 비-fret 보툴리눔 검정법 |
US9303285B2 (en) | 2012-01-04 | 2016-04-05 | Biomadison, Inc. | Methods and compounds for increasing sensitivity of botulinum assays |
US10908146B2 (en) | 2011-06-01 | 2021-02-02 | Biomadison, Inc. | Compositions and methods for improving sensitivity in cell based assays |
US9764009B2 (en) | 2011-06-13 | 2017-09-19 | Allergan, Inc. | Treatment of psychological trauma |
US20130171122A1 (en) * | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
LT2800973T (lt) * | 2012-01-04 | 2018-09-10 | Biomadison, Inc. | Būdai ir junginiai, skirti botulino tyrimų jautrumo padidinimui |
GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
WO2014100019A1 (en) | 2012-12-18 | 2014-06-26 | Allergan, Inc. | Prophylactic treatment of herpes recurrence |
US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
AU2015253045B2 (en) * | 2014-04-30 | 2020-07-16 | Allergan, Inc. | Formulations of biologics for intravesical instillation |
AU2015296256A1 (en) * | 2014-07-31 | 2017-03-02 | Allergan, Inc. | Formulations of biologics for intravesical instillation |
WO2017179775A1 (en) * | 2016-04-12 | 2017-10-19 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
HUE046290T2 (hu) * | 2016-09-13 | 2020-02-28 | Allergan Inc | Stabilizált, nem-fehérje clostridialis toxin készítmények |
KR101744900B1 (ko) | 2017-01-20 | 2017-06-08 | 주식회사 대웅 | 보툴리눔 독소를 포함하는 안정한 액상 조성물 |
RU2020101929A (ru) * | 2017-06-30 | 2021-07-30 | Аллерган, Инк. | Растворимые пленки для доставки активного агента |
WO2019152380A1 (en) * | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
CN112888454A (zh) * | 2018-09-13 | 2021-06-01 | 阿勒根公司 | 梭菌毒素-透明质酸组合物 |
GB201815817D0 (en) * | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
KR102259423B1 (ko) * | 2018-11-30 | 2021-06-02 | 주식회사 휴온스바이오파마 | 보툴리눔 독소의 안정화 액상 조성물 |
WO2020111852A1 (ko) * | 2018-11-30 | 2020-06-04 | 주식회사 휴온스글로벌 | 보툴리눔 독소의 안정화 액상 조성물 |
CN112812240B (zh) * | 2021-02-08 | 2022-03-15 | 武汉理工大学 | 一种超保坍后增强型保坍剂及其制备方法 |
CA3219084A1 (en) | 2021-07-08 | 2023-01-12 | Ishihara Sangyo Kaisha, Ltd. | Nematicidal composition |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
US6335023B1 (en) * | 1999-06-30 | 2002-01-01 | Ruey J. Yu | Oligosaccharide aldonic acids and their topical use |
KR100876060B1 (ko) | 1999-08-25 | 2008-12-26 | 알러간, 인코포레이티드 | 활성화가능한 재조합 신경독 |
US20030180289A1 (en) | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
US6500436B2 (en) | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
CA2494241C (en) * | 2000-02-08 | 2011-06-14 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
JP4632480B2 (ja) * | 2000-05-16 | 2011-02-16 | レドックス・バイオサイエンス株式会社 | チオレドキシン誘導物質 |
US7491799B2 (en) | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US7223577B2 (en) | 2000-11-17 | 2007-05-29 | Allergan, Inc. | Post-translational modifications and Clostridial neurotoxins |
US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
US7374896B2 (en) | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
JP2003119115A (ja) * | 2001-10-15 | 2003-04-23 | Kao Corp | 染毛剤組成物 |
US7183066B2 (en) | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
TWI260670B (en) | 2003-05-28 | 2006-08-21 | Futaba Denshi Kogyo Kk | Conductive sintered compact for fixing electrodes in electronic device envelope |
CA2558758C (en) | 2004-02-24 | 2015-06-23 | Allergan, Inc. | Botulinum toxin screening assays |
US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
EP1761558A1 (en) | 2004-06-30 | 2007-03-14 | Allergan, Inc. | Optimizing expression of active botulinum toxin type e |
GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
ES2479515T3 (es) * | 2004-07-26 | 2014-07-24 | Merz Pharma Gmbh & Co. Kgaa | Composición terapéutica con una neurotoxina botulínica |
GB2419527A (en) * | 2004-10-28 | 2006-05-03 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
AU2005271372B2 (en) | 2004-08-04 | 2012-05-03 | Allergan, Inc. | Optimizing expression of active botulinum toxin type A |
EP1830872B1 (en) | 2004-12-01 | 2010-11-17 | Health Protection Agency | Fusion proteins |
GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
WO2006059105A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Non-cytotoxic Protein Conjugates |
JP4913074B2 (ja) | 2005-03-03 | 2012-04-11 | アラーガン、インコーポレイテッド | 動物由来産物不含方法およびボツリヌス毒素を精製するための方法 |
CA2601577A1 (en) | 2005-03-15 | 2006-09-21 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
WO2008008082A2 (en) | 2005-09-19 | 2008-01-17 | Allergan, Inc. | Clostridial toxin activatable clostridial toxins |
CN101175478A (zh) * | 2005-10-06 | 2008-05-07 | 阿勒根公司 | 非蛋白稳定的梭菌毒素药物组合物 |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
EP2373294B1 (en) * | 2008-12-10 | 2016-04-20 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
-
2009
- 2009-12-10 EP EP09768315.5A patent/EP2373294B1/en active Active
- 2009-12-10 RU RU2011125601/15A patent/RU2535003C2/ru active
- 2009-12-10 AU AU2009339292A patent/AU2009339292B2/en active Active
- 2009-12-10 CA CA2746425A patent/CA2746425C/en active Active
- 2009-12-10 KR KR1020117015841A patent/KR20110106346A/ko not_active Application Discontinuation
- 2009-12-10 CN CN2009801563839A patent/CN102307571A/zh active Pending
- 2009-12-10 KR KR1020167022590A patent/KR20160103551A/ko not_active Application Discontinuation
- 2009-12-10 JP JP2011540900A patent/JP2012512162A/ja active Pending
- 2009-12-10 EP EP16164644.3A patent/EP3067049A1/en active Pending
- 2009-12-10 CN CN201610169541.6A patent/CN105833254A/zh active Pending
- 2009-12-10 WO PCT/US2009/067538 patent/WO2010090677A1/en active Application Filing
-
2015
- 2015-04-28 JP JP2015091341A patent/JP6424135B2/ja active Active
-
2017
- 2017-05-17 JP JP2017097975A patent/JP2017186348A/ja active Pending
-
2019
- 2019-03-05 JP JP2019039614A patent/JP2019108381A/ja active Pending
-
2021
- 2021-05-11 JP JP2021080591A patent/JP2021113233A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20110106346A (ko) | 2011-09-28 |
CN105833254A (zh) | 2016-08-10 |
WO2010090677A1 (en) | 2010-08-12 |
JP2012512162A (ja) | 2012-05-31 |
AU2009339292A1 (en) | 2011-07-07 |
JP6424135B2 (ja) | 2018-11-14 |
EP3067049A1 (en) | 2016-09-14 |
CA2746425C (en) | 2016-05-03 |
EP2373294A1 (en) | 2011-10-12 |
AU2009339292B2 (en) | 2016-01-21 |
JP2019108381A (ja) | 2019-07-04 |
KR20160103551A (ko) | 2016-09-01 |
EP2373294B1 (en) | 2016-04-20 |
RU2535003C2 (ru) | 2014-12-10 |
JP2021113233A (ja) | 2021-08-05 |
JP2015178505A (ja) | 2015-10-08 |
JP2017186348A (ja) | 2017-10-12 |
CN102307571A (zh) | 2012-01-04 |
CA2746425A1 (en) | 2010-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011125601A (ru) | Фармацевтические композиции токсина клостридий | |
JP6005239B2 (ja) | ボツリヌム毒素の凍結乾燥製剤 | |
WO2010100200A3 (en) | Lyophilised antibody formulation | |
PH12016501002A1 (en) | Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody | |
WO2008150479A3 (en) | High temperature stable peptide formulation | |
RU2012125254A (ru) | Составы антитела | |
PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
NZ596367A (en) | Lyophilized therapeutic peptibody formulations | |
WO2012076670A3 (en) | Antibody formulation | |
WO2013164789A3 (en) | Lyophilised and aqueous anti-cd40 antibody formulations | |
EP4339212A3 (en) | Subcutaneous anti-her2 antibody formulation | |
FI3769781T3 (fi) | Stabiili anti-ifnar1-formulaatio | |
AR040881A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-alfa | |
DK1766003T3 (da) | Thrombinpræparater | |
CA2774094A1 (en) | Formulations of daptomycin | |
RU2015104495A (ru) | Жидкая композиция длительно действующего конъюгата инсулина | |
RU2013128277A (ru) | СТАБИЛЬНЫЕ ИММУНОГЕННЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Staphylococcus aureus | |
US11040015B2 (en) | Method of long-term preservation of chemical and biological species using sugar glasses | |
WO2011035108A1 (en) | Formulations of daptomycin | |
ES2950497T3 (es) | Conservación de microorganismos | |
BRPI0821373B8 (pt) | composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas | |
RU2011122629A (ru) | Водная композиция, содержащая фолликулостимулирующий гормон | |
CN102949338A (zh) | 一种奶牛用稳定性强的5%聚维酮碘溶液及其制备工艺 | |
KR20130082464A (ko) | 의약 조성물 및 그의 제조 방법 | |
MX2021007393A (es) | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Changing information about inventors |